Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management

1 year ago 56

Subgroup analyses from non–small cell lung cancer clinical trials, such as the phase 3 POSEIDON and FLAURA2 trials, can help personalize treatment decisions with immunotherapy and targeted therapy based on individual mutational profiles.

1. Homepage
2. Brain Cancer
3. Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management